PRTA Prothena Corporation plc

13.64
-0.62  -4%
Previous Close 14.26
Open 14.21
Price To Book 1.88
Market Cap 544,189,092
Shares 39,896,561
Volume 170,711
Short Ratio
Av. Daily Volume 250,823
Stock charts supplied by TradingView

NewsSee all news

  1. Prothena Announces Appointment of Oleg Nodelman to its Board of Directors

    DUBLIN, Ireland, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Oleg Nodelman to its Board of Directors. "Oleg is a

  2. Prothena Reports Third Quarter 2019 Financial Results and Provides R&D Update

    Net cash used in operating and investing activities was $9.2 million in the third quarter and $38.9 million for the first nine months of 2019; quarter-end cash and restricted cash position of $393.0 million provides

  3. Prothena to Report Third Quarter 2019 Financial Results on November 5

    DUBLIN, Ireland, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2019 on

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 2020.
PRX002 (PASADENA)
Parkinson's disease
Phase 1b data released September 28, 2017 - insufficient meaningful clinical effect for further development.
PRX003
Psoriatic Arthritis
Phase 3 trial discontinued due to futility - April 23, 2018.
NEOD001 VITAL
AL Amyloidosis
Phase 2b trial did not meet primary endpoint - April 23, 2018.
NEOD001 PRONTO
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction
Phase 1 preliminary data safe and well tolerated - December 19, 2019. Additional data due 2020.
PRX004
ATTR amyloidosis

Latest News

  1. Prothena Announces Appointment of Oleg Nodelman to its Board of Directors

    DUBLIN, Ireland, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Oleg Nodelman to its Board of Directors. "Oleg is a

  2. Prothena Reports Third Quarter 2019 Financial Results and Provides R&D Update

    Net cash used in operating and investing activities was $9.2 million in the third quarter and $38.9 million for the first nine months of 2019; quarter-end cash and restricted cash position of $393.0 million provides

  3. Prothena to Report Third Quarter 2019 Financial Results on November 5

    DUBLIN, Ireland, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2019 on